Malignant or accelerated hypertension is the most severe form of hypertension, defined clinically by very high blood pressure (diastolic above 130 mm Hg) accompanied by bilateral retinal hemorrhages and/ or exudates, with or without papilledema. The aim of this review is to discuss if malignant hypertension still poses a clinically relevant entity and to highlight the diagnostic challenges of this form of hypertension. The substantial improvement in prognosis in patients with malignant hypertension over the last decades is well documented, but there is no strong evidence to suggest a significant change in its incidence. In fact, with the growing population and improving life expectancy, malignant hypertension is likely to become even more prevalent worldwide, especially in the developing countries with less advanced health care services. Despite simple diagnostic criteria of malignant hypertension, the diagnoses may be difficult in many patients. Malignant hypertension patients often have the diagnosis established only when the target organ damage occur. Furthermore, retrospective diagnosis is problematic, as malignant hypertensive retinopathy gradually resolves over a relatively short period of time, while persistent target organ damage will, however, lead to the development of complications and much poorer prognosis than in nonmalignant hypertension patients. Certainly, malignant hypertension still poses a clinically relevant and challenging form of hypertension and its possibility should be always considered during the assessment of patients with poorly controlled hypertension.
Hypertension is a major cardiovascular risk factor. Extreme elevation of systolic blood pressure (BP) and out of range office diastolic BP (above 130 mm Hg at the time of the diagnosis) are clinical features of malignant or so-called accelerated hypertension. To be diagnosed with this most severe form of the hypertension ocular changes have to be present: hypertensive retinopathy grades III or IV, according to the classification of Keith, Wagener, and Barker. 1, 2 Malignant hypertension has attracted attention of the clinicians due to virtually universal development multiorgan damage and, historically, very poor prognosis 3 (Figure 1 ). In this view, it has been recently proposed that ocular changes might not be the sole "diagnostic" type of the target organ damage to define malignant hypertension. It has been suggested to include other diagnostic criteria to facilitate the diagnostic process, the presence of an impairment of at least 3 different target organs (kidney, heart, brain, microangiopathy) and out of range elevation in systolic and diastolic BP. With this new definition, malignant hypertension is described as one of the clinical presentations of hypertension with multiorgan damage.
Early malignant hypertension diagnosis and immediate start or adjustment of the therapy is paramount for the better prognosis and preservation of the target organs function. The prognosis of malignant hypertension is very poor in the absence of treatment. However, despite use of currently available modern antihypertensive agents to provide adequate BP control prognosis in malignant hypertension patients is worse than in nonmalignant hypertension. The condition still represents an important clinical entity with significant consequences mainly due to the renal impairment, as well as brain and heart impairment. Malignant hypertension should be detected promptly, investigated, treated, and managed adequately to improve the patient's prognosis.
The aim of this review is to provide a summary on the current knowledge of malignant hypertension epidemiology, clinical features, and prognosis.
EPIDEMIOLOGY
The prevalence of malignant hypertension is low in the general population. Over the 5 decades of the observation around 1-2 new cases per 100,000 of population per year have been recorded in the malignant hypertension registry in Birmingham, United Kingdom. 4, 5 This largest prospective malignant hypertension registry has not demonstrated any noticeable reduction in the prevalence of malignant hypertension. A similar incidence of the new malignant hypertension cases has been reported from 3 large cohorts from Europe. [6] [7] [8] Among African-Caribbeans the incidence of malignant hypertension is generally higher with an overall of 7.3 per 100,000 of population per year. 6 A higher rate of malignant hypertension in the Black population may be due to their resistance to some antihypertensive medication as well as insufficient compliance with various treatments. Analysis of the US data from 2000 till 2011, collected by the largest all-payer Nationwide Inpatient Sample database of national discharges, did not showed any reduction in malignant hypertension incidence. 9 In fact, primary diagnosis of malignant hypertension increased after the 2007, with no increase in morbidity. Overall number of hypertensionrelated hospital admission increased from 2000 to 2011 and the rate of increase was much greater for the malignant hypertension and hypertensive encephalopathy. Regression model showed that the significant rate of increase for malignant hypertension and hypertensive encephalopathy was positive and for the essential hypertension was negative. The combined series for all 3 hypertensive groups did not show any significant change in the rate of increase. This finding very likely represents changes in coding practise, and subsequently an increase in costs, but not a true increase in the malignant hypertension incidence. At the very least no evidence in declining of the malignant hypertension incidence provided. The condition appears to have similar prevalence in the developed and developing countries, where it constitutes a significant cause of end-stage renal failure. [10] [11] [12] Pathogenically, in the majority of cases, malignant hypertension is due to essential hypertension; however, the secondary causes of malignant hypertension have also been reported. Younger patients more often presented with secondary causes of malignant hypertension, especially children under 16 years age. In children, the main causes of secondary form of malignant hypertension in two-thirds of cases being related to renal parenchymal disease and in one-third to aortoarteritis and fibromuscular dysplasia with only 5% of malignant cases attributed to essential hypertension. [13] [14] [15] In adults, cases of neoplasm of the juxtaglomerular area and Takayasu's arteritis involving renal artery have been reported. [16] [17] [18] Interesting observations have been reported in women where an association between the use of oral contraceptives and cigarette smoking and development of malignant hypertension been observed. 19 It is hard to explain the pathophysiological mechanisms and this association may exacerbate preexisted hypertension than serve as isolated factor of malignant hypertension development per se.
Along with the specific mechanisms of BP elevation in patients with malignant hypertension, there are common pathways shared with essential hypertension, such as endothelial dysfunction, platelet activation, elevated fibrinogen levels, and lipid abnormalities. [20] [21] [22] [23] [24] Some data indicate that extreme elevation of BP predominantly occurs in patients with long-standing poorly controlled essential hypertension and in some cases after the discontinuation of the medication. 25 There is also an evidence that malignant hypertension could develop de novo, without prior history of hypertension with the proportion of de novo diagnoses ranging from 55.7% 26 to 60%, in different registries. 27 These 2 groups of the malignant hypertension patients had similar signs and symptoms at the time of the presentation, with no difference in the level of BP and renal function. Also, the long-term survival was not significantly different between the de novo malignant hypertension patients and patients with the previously know hypertension history. 26 
PROGNOSIS
Initially patients with malignant hypertension, in the absence of treatment, had very poor prognosis, as the mortality was around 80% at 2 years. 1, 28 This very poor prognosis has been reflected in the characterization of the hypertensive patient as being "malignant. " Ethnicity has a significant impact on the survival of patients with malignant hypertension, males of African-Caribbean origin had a worse prognosis, possibly reflecting more severe renal impairment and higher BP at presentation and follow-up. 29, 30 The development of the new more efficient and tolerable antihypertensive drug therapy has meant that this prognosis is significantly improved, but the risk for the renal failure and different cardiovascular complications is still significant.
The demographic characteristics of the new malignant hypertension cases have not significantly changed over the last decades, based on the registry including 5,725 personyears of observation. 5 In particular, very similar levels of systolic BP were recoded at the time of the presentation in the patients seen before 1977 and between 1977 and 2006. Importantly, the 5-year survival has increased dramatically, showing continuous improvement starting from 1977 from 32.0% survival and increasing to 91.0% survival for the presentation with malignant hypertension between 1997 and 2006. However, in comparison to the nonmalignant hypertensive patients, all-cause mortality in patients with malignant hypertension was significantly higher (P < 0.01) with a higher rate of renal impairment. 31 The important patients characteristics as evident by multivariable analyses that put such patients at higher risk were age, baseline creatinine, and follow-up systolic BP (all P < 0.0001). Indeed, the tight BP control at follow-up independently significantly improves survival over the long-term in patients with malignant hypertension. 29 The West Birmingham Malignant hypertension registry revealed that the kidney failure is the primary cause of death in patients with malignant hypertension.
CLINICAL PICTURE
Malignant hypertension phase is one of the hypertensive emergencies. When patients are at malignant phase they usually would present with the severe elevated of systolic and out of range diastolic BP, and hypertensive retinopathy. The duration of the malignant phase varies, but on average it lasts up to 2 to 3 months. 32 The average elevation in BP is different at the time of the diagnosis, in the West Birmingham Malignant Hypertension Registry mean systolic and diastolic BP was 229 ± 30 mm Hg and 142 ± 19 mm Hg, respectively. 4 Interestingly, the introduction of new antihypertensive medications did not have a significant impact on the average level of systolic and diastolic BP at presentation and it have remained surprisingly similar (average BP 228/142 mm Hg) over the long follow-up period. 4 Although diastolic BP above 130 mm Hg is a standard diagnostic criterion of malignant hypertension, it should not be used rigidly. Occasionally patients with genuine malignant hypertension may have lower diastolic BP in presence of very high systolic BP (e.g., more 200 mm Hg) and typical eye changes.
The main histological feature of malignant hypertension is fibrinoid necrosis of arterioles in various tissues, including the kidney, accompanied by proliferative endarteritis in renal interlobular arteries. The above changes leads to the narrowing of the lumen and severe ischemic dysfunction of the glomerular tufts, triggering the activation of the renin-angiotensin system, leading to vasoconstriction and further progression of hypertension.
During the malignant hypertension phase, the first symptoms usually are visual disturbances, accompanied, in some cases, by cerebral symptoms. Presence of these symptoms in subjects with very high BP should always be treated with suspicion of possible malignant hypertension. The presentation and diagnosis of malignant hypertension is often delayed as the patients tend to develop clinical symptoms only at a later stage of their disease. 28, 33 In primary care settings, up to 75% of patients with malignant hypertension is underdiagnosed and many of these patients would only ask for an appointment the physician when they develop serious target organ damage and other complications. 10 2 A simplified classification of the hypertensive retinopathy divided all retinal changes into grade A and grade B. Grade A, characterized by arteriolar narrowing and focal constriction and correspond to nonmalignant hypertension changes. With grade B changes linear flame-shaped hemorrhages, and/or exudates, and/or cotton wool spots with or without papilledema presented and correspond to malignant hypertension. 34 This more simple and pragmatic description of fundoscopic findings has direct implication for management of hypertensive patients.
It needs to be emphasized that retinal fundoscopy has to be performed in all patients with severe hypertension at the time of the presentation. The specific malignant hypertension retinopathy does not persist for longer that for 2-3 months and it starts to regress gradually upon initiation of the antihypertensive treatment. 32 Thus, the rapid disappearance of typical retinal changes clearly limits the retrospective diagnosis of malignant hypertension. 32 Of note, not all malignant retinopathies are completely reversible, an association have been reported between the development of irreversible ocular complications and very high BP at the time of diagnosis, with prominent visual disturbance at presentation, and prolonged duration of the symptoms. 35 Ocular complications of malignant hypertension are common, ranging from incomplete recovery of the vision to more serious events such as central retinal artery occlusion and anterior ischemic optic neuropathy. 35, 36 Animal models of malignant hypertension confirm that the retinopathy develops a long time before the optic neuropathy and choroidopathy. 37 In extremer cases, malignant hypertension patients could develop retinal detachment of macula. 38 However, not all patients with extreme signs of malignant hypertension (i.e., hypertensive encephalopathy) would develop "malignant" retinopathy and grade 3-4 changes may be absent in some subjects during their initial examination. 39 This reflects the dynamic nature of the retinal changes. Of note, animal data of malignant hypertension models, described the presence of focal intraretinal periarterial transudates as the retinal changes specific to malignant hypertension. 40 In order to provide a timely diagnosis of this dangerous complication, repeated fundus examinations might be considered, particularly if BP fluctuates substantially. 41 The differential diagnosis with uncontrolled hypertension will be the signs of isolated bilateral papilledema without hemorrhages. It should be remembered that patients with connective tissue disorders, infective endocarditis, and severe anemia also could have retinal hemorrhages and papilledema. 41 Also, if patients develop diabetic retinopathy, the differential diagnosis of the retinal changes might be very problematic.
The degree and dynamic of the malignant retinopathy correspond to the changes of the renal function, thus emphasising the fact that patients with malignant hypertension develop systemic microvascular dysfunction, involving several organs. 36, 42, 43 
THE KIDNEYS
The renal function is impaired in patients with malignant hypertension. Histological studies have shown that 2 categories of the characteristic lesions of malignant hypertension present in the kidneys. The first type of lesion is intrarenal fibrinoid necrosis of small afferent arterioles, containing the necrotic remains of the smooth muscle cells as well as fibrin, platelet deposits, and intramural hemorrhage. [44] [45] [46] [47] The second type of lesion is a proliferative endarteritis of mediumsized and small arteries, containing proliferated smooth muscles cells and myofibroblasts. This lesion is called "onion skin. " All together these changes lead to the narrowing of the lumen and severe ischemia. Severe intrarenal vascular lesions accompanied by signs of nephritis parallel with clinical manifestation of malignant hypertension. 48 Marked activation of renin-angitensin-aldosterone system is evident in patients with malignant hypertension. There is evidence that irrespectively of the BP level elevation in plasma renin activity and an angiotensin 2-dependant aldosterone secretion was more profound in patients with malignant hypertension than in patients with severe hypertension. 49, 50 Furthermore, plasma renin activity and aldosterone level correlate with the markers of the microangiopathic hemolysis. 50 Although the exact pathophysiology of the marked elevation of the renin in malignant hypertension are still a matter of debate, the juxtaglomerular ischemia is the primary mechanism leading to the activation of the renin-angiotensin-aldosterone system. 51 The case report of malignant hypertension, with the massive increase in plasma renin activity and aldosterone was due to the neoplasm from the juxtaglomerular area. 18 Successful nephrectomy resulted in reduction of the renin and aldosterone concentrations and normalisation of the potassium levels. In patients with glomerulonephritis, malignant hypertension is commonly the first clinical manifestation. 52, 53 The incidence of malignant hypertension is higher if glomerulonephritis, particularly in its IgA type, associated with HIV. 53 High plasma renin activity, features of microangiopathy and renal dysfunction in patients with malignant hypertension parallel the reninmediated arteriolar damage and kidney dysfunction. 50 Unfortunately, the very first presentation of malignant hypertension could be acute renal failure. 46, 47, 54 Marked rise in serum creatinine or urea, as well as evidence of the proteinuria by dipstick, provide proof of the renal damage. In the West Birmingham Malignant Hypertension Registry, acute renal failure, defined as serum creatinine 300 mmol/l or more, was the first presentation in 32% of patients, and dipstick proteinuria has been reported in 63% of patients at the time of the diagnosis. 4 The deterioration of the renal function is not unusual even in treated patients, with a significant rise in median serum urea and creatinine levels over the long follow-up period. 26, 55, 56 Furthermore, the independent predictors of adverse outcomes in multivariable model is elevated serum creatinine and urea levels. 29 Progressive renal function decline leading to end-stage renal disease remains a significant threat to patients with malignant hypertension. The tight BP control over the long follow-up period is a major factor for preserved renal function. 56, 57 
VASCULAR SYSTEM
The key element of the vascular biology is the endothelium. Endothelium dysfunction on the macrovascular and microvascular level is one of the abnormalities seen in patients with malignant hypertension. 58 Excessive endothelial injury, along with activation of the renin-angiotensin-aldosterone system and impairment in intravascular prothrombotic state (agglutination/coagulation), result in the development of thrombotic microangiopathies. 59, 60 Thrombotic microangiopathy leads to thrombocytopenia and microangiopathic hemolytic anemia (anemia accompanied by higher lactic dehydrogenase and schistocytes in peripheral blood smear) causing further microvascular dysfunction and organ ischemia. The presence of thrombotic microangiopathy is associated with worse recovery of renal function longer team. 61, 62 In small group study, an association of thrombotic microangiopathies and elevation in plasma aldosterone level have been observed with no association with renin activity. 59 Thus, elevation of the aldosterone level could be a potential marker of the magnitude of organ damage, due to the thrombosis.
Many cardiovascular beds are predisposed to the extreme and rapid BP elevation resulting in multisystem complications. Features of target organ damage are not uncommon in these patients at presentation and could indicate prolonged history of BP elevation. Most such patients would have essential hypertension but a possibility of malignant phase transformation should be kept in mind.
HYPERTENSIVE ENCEPHALOPATHY
Hypertensive encephalopathy is a rare hypertensive emergency and it is characterized by acute neurological changes. Rapid elevation of cerebral perfusion pressure results the failure of the autoregulation of cerebral circulation leading to the high volume overload, impairment of blood-brain barrier function and resulted in brain edema. 25 The above pathophysiological changes happens on the background of impaired macrovascular and microvascular function. 58 It is important to remember that encephalopathy in malignant hypertension is a life-threatening condition and it always requires hospital admission.
The first main signs and symptoms of malignant hypertension encephalopathy are sudden onset of headache, nausea, and vomiting. This is followed by development of different visual disturbances, field loss, which in some cases it might be accompanied by neurological symptoms (restlessness, confusion and, in extreme, seizures, and coma). 25, 63 Additional diagnostic tests are very limited and not specific, such as increased pressure of the cerebrospinal fluid, evidence of white matter edema on computed tomography or magnetic resonance imaging scans and these changes would resolve after patient stabilization. 25, 64 In a recent retrospective analysis of the US data, the increasing trend for the hospital admission of patients with either hypertensive encephalopathy or malignant hypertension after 2007 have been observed, with no increase in morbidity. 9 These observations could reflect improved differential diagnoses of malignant hypertension with encephalopathy, as admissions for essential hypertension fell.
THE HEART
Impairment of cardiac structure and function is evident in patients with malignant hypertension. Electrocardiogram criteria of left ventricular hypertrophy were present in 77% of patients in the West Birmingham Malignant Hypertension Registry. 4 In the same cohort chest X-ray revealed presence of cardiomegaly in 47% of cases. Echocardiography showed the features of the left ventricular hypertrophy and the signs of impaired systolic function, measured by global longitudinal strain. 27 Systolic impairment, evident in 52% of patients, improved significantly after 2 months of the treatment initiation and restored completely at 1 year of the follow-up. The regression of the left ventricular hypertrophy has been seen as early as 2 months after the treatment. 27 However, the degree of the left ventricular hypertrophy and features of diastolic dysfunction on tissue Doppler, were still present after almost a year of the treatment. Long-term treatment with good BP control, results in further, although typically not complete, regression of the left ventricular hypertrophy and improvement of diastolic dysfunction, with preserved systolic function. 65 Although left ventricular hypertrophy may at least partly reflect an adaptive response to persistently raised BP, its presence is associated with unfavourable prognosis. 29 Of note, some patients do have normal radiographs, electrocardiograms, or echocardiograms despite very high BP, suggesting that the onset of the BP elevation was acute with no time for the target organ damage occurrence. 4, 26, 66 Long-term cardiac compilations are relatively rare in patients with malignant hypertension, but still about 11% of patients develop heart failure, and around 4% of patients develop angina, or myocardial infarction. 4 Hypertension causes heart failure by a number of mechanisms, including pressure overload on the heart due to the raised peripheral vascular resistance, reduced left ventricular compliance (for example, in left ventricular hypertrophy), an increased risk for coronary artery disease and the precipitation of cardiac arrhythmias (such as atrial fibrillation). Severe hypertension results in a significant increase in afterload and may result in decompensation of the failing heart.
CONCLUSION
Recent improvements in the general management of hypertension, including the lifestyle intervention have not translated into the reduction of malignant hypertension incidence. Furthermore, with the growing population and improving life expectancy, malignant hypertension is likely to become even more prevalent worldwide, especially in the developing countries with less advanced health care services. Despite simple diagnostic criteria of malignant hypertension the diagnosis is frequently missed during the initial presentation in many patients. As a result, patients with malignant hypertension have the diagnosis established only when the target organ damage occur. Furthermore, malignant hypertensive retinopathy gradually resolves over a relatively short period of time, that makes a retrospective diagnosis very problematic. The target organ damage will, however, persist in these patients, leading to the development of complications and much poorer prognosis than in nonmalignant hypertension patients. Certainly, malignant hypertension still poses a clinically relevant and challenging form of hypertension and its possibility should be always considered during the assessment of patients with poorly controlled hypertension.
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